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Lumbar myelogram utilizing nonionic contrast is a commonly performed procedure to identify spinal pathology. Complication
rates are low. Cerebral edema has been shown to occur following intrathecal injection of ionic contrast; however, no current
literature has documented this complication relating to the ubiquitously used nonionic contrast medium. We report a case of
a patient who developed malignant cerebral edema following a lumbar myelogram with Isovue-M 300 nonionic water-soluble
intrathecal contrast. We believe this is the ﬁrst reported case of cerebral edema resulting from the use of a nonionic contrast.
1.Introduction
The neurotoxicity of inadvertent intrathecal injection of
ionic contrast media during myelography is well docu-
mented. To our knowledge, there are no known case reports
detailing malignant cerebral edema as a response to lumbar
myelography using nonionic contrast media. We report a
patientwhodisplayedalteredmentalstatusandradiographic
evidence of severe brain edema following myelography using
nonionic contrast.
2.CaseReport
A 50-year-old African-American woman presented with
increasedsomnolence,headache,visionchanges,andnausea.
One day prior she had undergone a L2-L3 interspace lumbar
puncture in the prone position using a 25-gauge spinal
needle with infusion of 10mL of Isovue-300 nonionic
contrast at a concentration of 61.2 grams iopamidol/100mL
equivalent to 300mg iodine/mL. The patient was placed
prone following the myelogram. There was no history of
new medication, trauma, or complications during her recent
procedure.
At presentation, the patient denied meningismus, photo-
phobia, or seizure activity. Past medical history was positive
for cervical spondylosis, hyperlipidemia, hypertension, and
mitral valve regurge. She was considered to be in good health
prior to the procedure. Surgical history included a C3–C6
anterior cervical fusion four months prior to presentation.
She was complaining of neck and upper extremity pain,
which was the indication for the myelogram. Her only
reported allergy was to Naproxen. Current medication
included aspirin, Colace, Cymbalta, Neurontin, Vicodin,
Lisinopril, Prilosec, Senokot, Zocor, and Ultram.
Following the myelogram, the patient was observed for
six hours in the postprocedure area. She was discharged in
stable condition, with no complaints. She returned to the
emergency room six hours later, complaining of a postural
headache, which progressed to diminished mental status. A
physical exam was positive for lethargy, absent spontaneous
retinal venous pulsation, and sluggishly reacting pupils bilat-
erally. Her vitals as well as standard laboratory values were
all within normal limits. Computed tomography (CT) scan
of the head demonstrated marked bihemispheric cerebral
edema with obliteration of the basal cisterns and cerebral
sulci (Figure 1).2 Radiology Research and Practice
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Figure 1: (a, b) Axial CT scans demonstrating diﬀuse cerebral edema on admission.
The patient was admitted to the neurosurgical intensive
care unit and was immediately started on dexamethasone
and mannitol. Serial CT scans gradually showed edema
resolution corresponding to the patient’s slow return to
baseline neurological exam. She was discharged on hospital
day ﬁve with a decadron taper. Her neurologic examination
a n ds e n s o r i u mw a sn o r m a lt w ow e e k sa f t e rt h ep r o c e d u r e
and remains so one year after the event.
3. Discussion
Cerebral edema is deﬁned as an increase in brain water
content above the normal content of approximately 80%
and is invariably a response to a primary brain insult
[1]. Cerebral edema can lead to increased intracranial
pressure as well as movement of the intracranial contents,
which can cause injury by compression and mechanical
manipulation. When cellular function cannot be sustained
due to inadequate delivery of nutrients, such as that caused
by global ischemia resulting from massive edema, a series
of biochemical reactions called the ischemic cascade begins
within the cerebrum.
Signs and symptoms of cerebral edema can vary widely.
Some of the more common ﬁndings in patients include
abnormal response to pain, decorticate or decerebrate pos-
ture, altered mentation, sustained heart rate deceleration
(more than 20 beats/minute (bpm)), vomiting, headache,
and lethargy or not being easily awakened [2]. Close
bedside monitoring is required, focusing on the level of
consciousness and new or worsening focal neurological
deﬁcits; the patient may need to be admitted to the intensive
care unit [1]. Serial CTs and MRIs may conﬁrm worsening
of cerebral edema, intracranial compartmental and midline
shifts, herniation syndromes, and ischemic brain injury. This
neuroimaging can also help diﬀerentiate the type of edema
present, whether focal or global, and involvement of gray or
white matter [1, 3].
Lumbar myelography is a common procedure used
to evaluate spinal pathology. Its use has declined over
the past decade due to the availability of high-ﬁdelity
magnetic resonance imaging (MRI) [4]. Myelography is
considered safe, having a low risk of seizures, contrast
reactions, bleeding, or other postmyelography complications
[4]. Adverse reactions to contrast agents can be mild to life
threatening; the contrast agents most likely to cause adverse
reactions are those with higher osmolality, and ionic agents
have two times more osmolality than nonionic agents [5].
However, low-osmolality agents cost up to 10 times more
than high-osmolality ionic agents [5]. The ionic nature of a
contrastmediumistheprimarycauseofneurotoxicity;other
elements involved include the dosage and concentration,
the duration of exposure, and its osmolality [6]. There are
numerous well-documented cases reporting seizures and
encephalopathy with use of metrizamide [7], which was
introduced in 1969 as the ﬁrst nonionic water soluble
contrast. Later development of iohexol and iopamidol in
the late 1970s replaced metrizamide due to a lower risk
of adverse neurological eﬀects [8–10]. In 1986, Elkin et al.
reported no cases of mental status changes or seizures in 248
patients after iohexol myelography [9]. In 1988, two large
case series of iohexol lumbar myelographies were reported,
and no serious neurologic complications were observed; in
addition, the side eﬀects of headache, nausea, and vomiting
were postulated to be the result of the spinal puncture
itself rather than the contrast medium [11, 12]. Torvik and
Walday noted that speciﬁc contrast-induced mechanisms
may indeed be partly responsible for the headache and
vomiting, because those symptoms occur with diﬀerent
frequencies after injection of various types of contrast media
[10]. A small number of case reports discussing the use
of nonionic mediums document seizures [13–21], aseptic
meningoencephalitis [22–25], aseptic meningitis [26–29],
and encephalopathy [7, 30].
Several case reports have documented neurotoxicity fol-
lowing angiography using nonionic contrast media, includ-
ing encephalopathy [31, 32], cerebral edema [32], selective
cortical injury [33], and transient partial amnesia [34].
Donaghy et al. suggested that disruption of the blood-brain
barrier occurs during angiographic use of nonionic con-
trast, allowing diﬀusion into the parenchyma, thus exertingRadiology Research and Practice 3
a neuronal toxic eﬀect resulting in acute encephalopathy
[30]. Frontera et al. reported a case of contrast-induced
neurotoxicity and postulate that the toxicity may have been
exacerbated by a slower washout of the CM, and there may
havebeenanimmune-mediatedhypersensitivitymechanism
as well as selective cortical sensitivity to contrast materials.
In addition, the authors theorize that delayed apoptotic
infarction may have played a role in the development of
the neurotoxicity [33]. Sawaya et al. reported a case of
contrast-induced encephalopathy, theorizing it secondary to
seepage through the BBB by mechanisms not including the
contrast osmolality; this seepage then resulted in temporary
disruption of the central cholinergic synaptic transmission
[31].Guimaraens et al.reporteda caseof cerebraledemaand
transient encephalopathy caused by the use of nonionic CM
in angiography for treatment of a cerebral aneurysm. The
authors consider the neurotoxicity as secondary to the vol-
ume of contrast medium used, as well as to the patient’s his-
tory of hypertension, which predisposed him to disruption
of the BBB and cerebral autoregulatory dysfunction [32].
The neurotoxicity of inadvertent intrathecal injection
of ionic contrast media during myelography is well docu-
mented [35–54]. There is a paucity of the literature, however,
concerning the pathophysiology of the rare but severe
adverse neurological conditions that have been attributed to
the use of intrathecal injection of nonionic contrast media.
As various neurotoxic eﬀects can be seen in both
rodents and humans, neurotoxic studies in rodents may have
predictive value for neurotoxic eﬀects in humans [55]. In
their study of adult rabbits having had intrathecal injection
of both ionic and nonionic contrast media, Lee et al. found
subpial edema as well as acute and chronic inﬂammation;
these conditions were most severe after ionic injection and
milder after nonionic injection [56]. Miyazawa et al. infused
rat blood with an ionic CM, which deformed red blood
cells and in turn induced cerebral edema, destruction of
the BBB, and animal death. The infusion of nonionic CM
into rat blood had less eﬀect on the red blood cells, and
no cerebral damage was seen in these rats [57]. Mennini
et al. compared the binding properties of two nonionic
CM in vitro on select rat brain areas to evaluate whether
CM-related neurotoxicity derived from their interactions
with speciﬁc receptors on neural membranes. The authors
concluded that the nonionic CM did not inﬂuence normal
neural membrane functions; nonionic CM had no eﬀect
on the binding capacities of the receptors for common
neurotransmitters. The authors postulate that the occasional
neurotoxic eﬀects seen with nonionic CM do not occur as a
consequence of speciﬁc action on brain receptors, but that
nonionic CM may have an indirect, postmembrane site of
action. The authors determined it unlikely that nonionic
CM exert their neurotoxic eﬀects through speciﬁc binding
to neurotransmitter receptors [58]. Wible Jr. et al. compared
the neurotoxicity of four nonionic contrast materials, similar
in osmolality and viscosity, injected into 124 adult rats.
The authors found that the nonionic material with smaller
degrees of hydrophilicity tested (iopromide) produced the
highest degree of neurotoxicity [59]. Luzzani et al. com-
pared the acute toxicities of monomer and dimer nonionic
contrast media injected into mice and rats to evaluate the
determinants ofneurotoxicity. The median lethaldose values
obtained by Luzzani et al. were similar to those obtained
by Wible et al. and Luzzani et al. concluded that the
neurotoxicity of nonionic CM is due more to characteristics
of chemical structure other than hydrophilicity, than on
the physicochemical characteristics of their solutions. In
other words, the neurotolerability of nonionic CM depends
more on the chemical structure of the CM than on the
physicochemical characteristics of the CM. Diﬀerences in
hydrophilicity between CM molecules did not account for
the diﬀerences in their neurotolerability [55].
Current theories of the pathophysiology of neurotoxicity
due to intrathecal use of nonionic contrast include direct
neurotoxicity [23], serum osmolarity diﬀerences, [30]a n d
lipid solubility of the agent [60]. According to guidelines
by the American College of Radiology, patients with any
of the following listed conditions should be considered
for low-osmolality nonionic contrast agents: advanced age,
food or medication allergies, hay fever or asthma, previ-
ous anaphylactoid reaction to contrast material, treatment
with nephrotoxic agents, preexisting renal insuﬃciency, or
multiple medical problems or an underlying disease [61].
Our patient had none of these conditions, nor did she
have any identiﬁable risk factors for seizure, encephalitis,
or hemorrhage. We postulate that the mechanism for our
patient’s acute onset of massive cerebral edema is due to the
dysfunction of the patient’s BBB, with subsequent loss of
autoregulation of cerebrovascular blood ﬂow and resulting
vasogenic edema from hyperemia. Further elucidation of
the mechanisms responsible for the development of severe
neurological adverse events is needed.
3.1. Treatment. Treatment of vasogenic edema includes both
steroid administration and osmotherapy [1]. The osmotic
gradient created by osmotherapy induces the movement of
water from the brain extracellular compartment into the
vasculature; this then improves intracranial elastance and
decreases intracranial volume [1]. In a normal individual,
brain volume makes up 80%, blood volume makes up 10%,
and CSF volume makes up 10% [1, 62]. The traditional
recommendation for patients with increased intracranial
pressure is osmolality in the range of 300–320mOsm/L
[1, 62, 63].
An osmotic agent is considered ideal if it is inert,
nontoxic,hasfewsystemicsideeﬀects,andcreatesafavorable
osmotic gradient by remaining in the intravascular com-
partment [1, 62, 64–66]. Another important characteristic
of an ideal osmotic agent is the ability of an intact BBB to
exclude the agent, quantiﬁed by the reﬂection coeﬃcient σ;
the range of the potential coeﬃcients is 0 (freely permeable)
to 1 (entirely excluded). The risk of rebound cerebral edema
is greater as the BBB permeability of the agent increases
[67]. Osmotic agents with σ approaching 1 are completely
excluded by an intact BBB and are less then likely to cause
rebound edema [1, 65, 66].
Rebound cerebral edema may occur with mannitol
(σ = 0.9) use, because in areas in which the BBB is not
intact,theosmoticgradientisreversedbetweenthebrainand4 Radiology Research and Practice
the intravascular compartment [1, 64]. Studies have shown
that mannitol appears in the CSF at approximately 12% of
the corresponding plasma concentration eight hours after IV
administration [1, 68], and rebound increases in ICP with
mannitol use are well documented [1]. Glycerol (σ = 0.48)
and urea (σ = 0.59) have transient osmotic eﬀects and are
only partly excluded by the intact BBB; therefore, they are
not ideal agents for osmotherapy [1]. Sodium chloride has
been proposed as a more eﬀective osmotic agent because it
has a reﬂection coeﬃcient of 1.0 [1, 64, 69].
No guidelines exist for ICP monitoring in cerebral
edema attributed to intrathecal drug administration; rather,
decisions regarding ICP monitoring are often based on
results of neuroimaging studies as well as the neurological
status of the patient [1]. An algorithmic approach is utilized
in the medical management of cerebral edema with or
without elevated ICP. General measures include avoiding
dehydration and systemic hypotension, maintaining normal
body temperature, and positioning the head and neck so that
intracranialvenousoutﬂowisfacilitated.Speciﬁctherapeutic
interventions include osmotherapy, controlled hyperventi-
lation, administering corticosteroids or diuretics, and sup-
pressing cerebral metabolism with pharmacology [1].
4. Conclusion
We present a case of malignant cerebral edema following CT
myelogram using a nonionic water-soluble iodinated con-
trast agent administered intrathecally. This is an unheard-
of complication with the use of a nonionic contrast agent.
Clinicians should be aware of this rare, but potentially fatal,
complication of this commonly performed procedure.
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